Trials
Sites
Patients Enrolled
Countries
What we do
ANZUP is the leading cancer cooperative clinical trials group that brings together all of the professional disciplines and groups involved in researching and treating below the belt (penile, bladder, kidney, prostate and testicular) cancers and conduct high quality clinical research.
ANZUP identifies gaps in evidence and areas of clinical need, collaborates with the leading clinicians and researchers in below the belt cancers, and communicate frequently and effectively with the broader community along the way.
What we do
ANZUP is the leading cancer cooperative clinical trials group that brings together all of the professional disciplines and groups involved in researching and treating below the belt (penile, bladder, kidney, prostate and testicular) cancers and conduct high quality clinical research.
ANZUP identifies gaps in evidence and areas of clinical need, collaborates with the leading clinicians and researchers in below the belt cancers, and communicate frequently and effectively with the broader community along the way.
Telehealth and Teletrials
Teletrials builds on the telehealth model and increases access to clinical trials for people with cancer living in rural and remote locations, or in self-isolation due to COVID-19. Teletrials also allows trials recruitment and activity to continue.
Teleheath and Teletrials
Teletrials builds on the telehealth model and increases access to clinical trials for people with cancer living in rural and remote locations, or in self-isolation due to COVID-19. Teletrials also allows trials recruitment and activity to continue.
Latest News
Three-year follow up results from the TheraP study for people with metastatic prostate cancer shows continued benefits
The Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP) reports the three-year follow up results of its TheraP (ANZUP 1603) clinical trial
The updated results from the ENZAMET clinical trial show a clinically meaningful survival benefit from novel hormone therapy for people with metastatic hormone sensitive prostate cancer
The Australian-led clinical trial ENZAMET has shown that the addition of hormone therapy with a medicine called enzalutamide to standard therapy (ADT alone to ADT
ASCO Reading Room Thought Leader interview
In this exclusive MedPage Today interview, Eric A. Klein, MD, discusses Enzalutamide’s impact on overall quality of life.
Three-year follow up results from the TheraP study for people with metastatic prostate cancer shows continued benefits
The Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP) reports the three-year follow up results of its TheraP (ANZUP 1603) clinical trial
The updated results from the ENZAMET clinical trial show a clinically meaningful survival benefit from novel hormone therapy for people with metastatic hormone sensitive prostate cancer
The Australian-led clinical trial ENZAMET has shown that the addition of hormone therapy with a medicine called enzalutamide to standard therapy (ADT alone to ADT
ASCO Reading Room Thought Leader interview
In this exclusive MedPage Today interview, Eric A. Klein, MD, discusses Enzalutamide’s impact on overall quality of life.